Yaƙi da Ciwon daji na Hepatocellular tare da Bioocus GPC3 CAR-T Therapy

Bayanin Majiyyaci

Pawan, wani mutum mai himma daga Indiya, an gano yana da cutar hanta mai tsanani wadda ta rikitar da cutar kansar hanta mai yawan focal (HCC) a watan Agusta na 2024. Yana da shekaru 67 a lokacin da aka gano cutar (yana cika shekaru 68 a lokacin magani), ya fuskanci wata cuta mai tsanani wacce ke da raunuka da yawa a hanta, alamun ƙari kamar AFP da PIVKA-II, anemia, rashin daidaituwar enzymes na hanta, da kuma metastases na ƙashi daga baya. Duk da cewa an yi masa transarterial radioembolization (TARE), transarterial chemoembolization (TACE), immunotherapy (Atezolizumab + Bevacizumab, Tremelimumab + Durvalumab), da kuma magungunan da aka yi niyya (Lenvatinib, Cabozantinib, Regorafenib), cutar ta ci gaba. Gwajin kwayoyin halitta ya nuna maye gurbi a cikin TP53, KRAS, CDKN2A, CTNNB1, da ARID1A, tare da ƙarancin bayyanar PD-L1 da rashin lafiyar HRD, wanda ke nuna ƙarancin amsawa ga wasu masu hana. Don neman mafita mai zurfi, an tura Pawan zuwa Asibitin Ciwon daji na Tianjin ta hanyar Bioocus don maganinmu na GPC3 CAR-T mai ɗauke da cutar kansa a ƙarƙashin lambar magani P1544.

Tafiyar Maganin

Maganin CAR-T na Pawan ya fara ne da cutar leukapheresis a ranar 11 ga Agusta, 2025, sannan aka ƙera shi da kuma jiko a ranar 2 ga Satumba, 2025. An ba shi allurar ƙwayoyin CAR-T guda 4.73 × 10^8, wanda aka yi niyya ga GPC3, wani alama da aka nuna fiye da kima a cikin HCC. Maganin jiko kafin jiko ya haɗa da fludarabine da cyclophosphamide don haɓaka aikin jiko. Bayan jiko, an sa ido kan jininsa na gefe don faɗaɗa CAR-T a ranakun 4 (D4), 7 (D7), 10 (D10), da 12 (D12).

• D4 (Satumba 6, 2025):Kwayoyin CAR-T a kashi 5.15% na ƙwayoyin CD3+ T (cikakken ƙima: 9.27 × 10^6/L), yana nuna farkon sassaka.
• D7 (Satumba 9, 2025):An kai kololuwa a 3.97% (6.12 × 10^7/L), yana nuna yawan aiki.
• D10 (Satumba 12, 2025):04% (9.07 × 10^6/L).
• D12 (Satumba 14, 2025):An daidaita a 2.82% (2.26 × 10^7/L), tare da jimillar ƙwayoyin T a 5.4 × 10^9/L, CD3+ a 14.87%, haɓaka ƙwayoyin T masu guba na CD8+ a 77.88%, da kuma daidaita ƙananan CAR-T (misali, 2.46% CD8+CARGPC3+/CD8+).

A lokacin da ake kwantar da shi a asibiti daga ranar 11 ga Agusta zuwa 15 ga Satumba, 2025, Pawan ya fuskanci wasu illoli masu sauƙi, ciki har da zazzabi mai ƙarancin ƙarfi (har zuwa 38.5°C), gajiya, da kuma ƙaruwar sinadarin hanta na ɗan lokaci, wanda aka yi masa ta hanyar tallafi ba tare da wata mummunar illa ga cytokine release syndrome ba (CRS grade 1) ko kuma gubar jijiyoyi. Alamomin da suka fi muhimmanci sun kasance masu karko, kuma kulawar tallafi ta haɗa da magungunan hana kamuwa da cuta, abinci mai gina jiki, da kuma sa ido kan matsaloli kamar ascites.

Sakamako Masu Kyau

Faɗaɗawar CAR-T, kodayake ƙarami ce, ta nuna juriya da aikin hana ƙari, tana da alaƙa da alamun ƙari masu ƙarfi kuma babu ci gaba nan take akan hoton da aka ɗauka. Shari'ar Pawan ta yi daidai da nasarar Bioocus a cikin GPC3 CAR-T don HCC, inda ko da juriya mai ƙarancin ƙarfi na iya haifar da martani mai ɗorewa ga marasa lafiya da ba sa iya jurewa. An sallame shi cikin yanayi mai kyau a ranar 15 ga Satumba, 2025, tare da shawarwari don ci gaba da sa ido, gami da alamun ƙari, aikin hanta, da kuma duban PET-CT. Hanyar da aka yi niyya ta wannan maganin ta rage guba ta tsarin yayin da take magance yanayin hanta.